newsfilter
← Earnings
Earnings Releases·

Silence Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported Q3 2026 net loss of $12.4 million ($0.08/share), a 41% decrease from $21.0 million in the prior year, driven by a 55% reduction in R&D expenses to $9.3 million and lower G&A costs of $4.9 million.
  • Entered into a definitive agreement on October 19, 2026, to be acquired by Merck KGaA, Darmstadt, Germany, with the transaction expected to close in Q1 2027 subject to customary conditions.
  • Cash and cash equivalents increased to $247.7 million as of September 30, 2026, following $201.3 million in gross proceeds from an upsized public offering announced in August 2026.
  • Delivered positive topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera, with data accepted for presentation at the ASH 2026 Annual Meeting in December 2026.
Company
SILENCE THERAPEUTICS PLC
Sector
Healthcare
Industry
Biotechnology